Enveric Biosciences Canada Inc.

Antheia, Inc.

Epimeron Inc.

Willow Biosciences, Inc.

Enveric Biosciences Canadainc.

Peter James Facchini

Jillian M Hagel

Chang-Chun Ling

Kaveh Matinkhoo

David James Press

Glynnis Elizabeth Jensen

Ye Cai

Xue Chen

Joseph Tucker

Jessica Bik-Jing Lee

Guillaume Arthur Welch Beaudoin

Scott Cameron Farrow

Jeffrey C Colbeck

Jillian Hagel

Thi Thu Thuy Dang

Joseph E Tucker

Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Substituted ethylamine fused heterocyclic mescaline derivatives

Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Fused heterocyclic mescaline derivatives

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids ('BIAs') such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof

Disclosed are novel aminated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The aminated psilocybin derivative compounds may be chemically synthesized.

Aminated psilocybin derivatives and methods of using

Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N-propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Substituted n-propylamine fused heterocyclic mescaline derivatives

Disclosed are novel N-heterocycle-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

N-heterocycle substituted tryptamine derivatives and methods of using

Disclosed are novel fused mescaline derivative compounds, notably C-substituted isopropylamine fused heterocyclic mescaline derivatives, including C-substituted isopropylamine fused dioxolane and fused dioxane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

C1-substituted isopropylamine fused heterocyclic mescaline derivatives

Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.

Hydroxylated psilocybin derivatives and methods of using

Polynucleotides and polypeptides useful in the manufacture of a class of chemical compounds known as alkaloids are provided. The polynucleotides and polypeptides may be used to synthesize alkaloids, including reticuline, thebaine and morphine, in vivo and in vitro. The polynucleotides further may be used to examine the presence of the polynucleotides in a cell or a cell extract, and to modulate expression thereof in living cells.

Polynucleotides and polypeptides useful for making alkaloid compounds

Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.

Halogenated psilocybin derivatives and methods of using

Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.

Multi-substituent psilocybin derivatives and methods of using

Disclosed are novel C-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

Growing community of inventors

Calgary, Canada

Peter James Facchini